BRD4 and neoplasm: Additionally, ARV-771 was shown to induce BRD4 and c-MYC degradation in 22Rv1 tumour xenografts in mice, and more importantly led to tumour regression in the 22Rv1 model following daily subcutaneous dosing of 30 mg/kg.